Search Tag: CEO of Masimo
2020 29 Jun
Drug-free Neurostimulation Device Reduces the Symptoms of Opioid Withdrawal Masimo today announced Bridge™, an opioid withdrawal solution that uses neuromodulation to aid in the reduction of symptoms associated with opioid withdrawal. Bridge, which has been granted an FDA De Novo classification, is the first evidence-based, drug-free, non-surgical...Read more
2020 25 Jun
Wearable, Wireless Patient Orientation, Activity, and Respiration Sensor Helps Clinicians Monitor Patient Position and Respiration Rate Masimo announced today that Centroid™, a wearable, wireless patient orientation, activity, and respiration rate sensor, has received FDA clearance. Centroid helps clinicians monitor patient position to avoid...Read more